Ipertensione polmonare: classificazione e patogenesi

Pulmonary hypertension is diagnosed when the resting mean pulmonary arterial pressure reaches 25 mm Hg or higher. This elevated pressure in the blood vessels transporting blood from the heart to the lungs can cause significant symptoms and lead to right heart failure. The condition affects overall quality of life and requires prompt medical evaluation.

Pulmonary arterial hypertension (PAH) is a rare, fatal form characterized by vascular changes in small arteries and arterioles, causing elevated pulmonary arterial pressure and vascular resistance. Unlike other PH types linked to left heart disease, lung disease, or blood clots, PAH involves distinct mechanisms including pulmonary vascular remodeling, sustained vasoconstriction, in situ thrombosis, and vascular wall stiffening.

Pulmonary vasoconstriction in PAH results from imbalanced vasoactive mediators. Decreased vasodilators like nitric oxide and prostacyclin reduce vessel widening, while increased vasoconstrictors like endothelin-1 (ET-1) promote narrowing and smooth muscle cell proliferation. This mediator imbalance drives sustained constriction and worsens vascular resistance.

Pulmonary hypertension symptoms include dyspnea (shortness of breath), fatigue, chest pain, and syncope (fainting). These symptoms typically worsen over time, progressively limiting patients' ability to perform routine activities. Early recognition of these signs is important for timely diagnosis and intervention.

Treatment for pulmonary arterial hypertension employs multiple mechanisms: cGMP signaling stimulators enhance vasodilation, nitric oxide therapies promote vessel widening, membrane receptor antagonists and agonists modulate vasoactive pathways, and ion channel blockers reduce vascular resistance. Treatment choice depends on PAH severity and patient health status.

The five PH classifications are: PH due to left heart disease, PH from lung diseases or hypoxia, chronic thromboembolic PH (caused by blood clots), PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension (PAH). Each classification relates to different underlying causes, treatment approaches, and prognoses, guiding clinical management decisions.

PAH involves multiple vascular structural changes: pulmonary vascular remodeling alters vessel architecture, sustained vasoconstriction narrows blood vessels, in situ thrombosis causes clotting within vessels, and vascular wall stiffening reduces elasticity. These combined changes increase pulmonary arterial pressure and vascular resistance, progressively impairing lung blood flow.